System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maria Buti is an expert in Hepatology at Vall d'Hebron Hospital Universitari (Spain). As of October 2026, ScienceLeadR ranks Maria Buti in the top 1% of experts worldwide for Hepatitis. Maria Buti has authored 1,072 publications, the most recent in 2026, and is an investigator in 38 clinical trials, 3 of them ongoing. SLR score: 4,536 (community average: 125). How the SLR is computed.

LeadR Profile

Maria Buti Vall d'Hebron Hospital Universitari Spain
4 536 ScienceLeadR Reputation 4536

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Infectiology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1988 - 2026
Source: PubMed

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1072

Citations

Citations: 45 937 1st author: 209 Last author: 172 Unique author: 23

Main journals

J Hepatol 361
Gastroenterol Hepatol 45
Gastroenterology 40
Aliment Pharmacol Ther 38
J Viral Hepat 37

Best Journals

J Hepatol 63
N Engl J Med 7
Lancet 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Reply to "Letter: From Genetic Association to Clinical Prediction in Chronic Hepatitis D" and "Letter: Interpreting HLA-A*11:01 and Persistent HDV Viraemia in the Context of Host, Viral and Treatment Heterogeneity".
PMID 42897735 — hepatitis d, hla-a antigens, hepatitis d, chronic, hepatitis, chronic, pharmacology, therapeutics, hepatitis		Aliment Pharmacol Ther20260
Sex Differences in Mortality Among Patients With Hepatocellular Carcinoma.
PMID 42826017 — liver diseases, mortality, carcinoma, hepatocellular, liver, sex characteristics, sex, hepatitis, sex differences		JAMA Netw Open20260
Changing epidemiology and etiology of hepatocellular carcinoma in Europe: implications for clinical practice and health policy.
PMID 42820245 — liver diseases, epidemiology, carcinoma, hepatocellular, neoplasms, liver, liver neoplasms		Lancet Reg Health Eur20261
Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice.
PMID 42819713 — carcinoma, hepatocellular, liver, diagnosis		Lancet Reg Health Eur20261
Emergency Department-Based Screening and Linkage-to-Care for Hepatitis B, C, and D in a Referral Hospital in Barcelona, Spain: Reduction in Hepatitis C Prevalence After Five Years.
PMID 42797761 — hepatitis c, emergencies, virology, prevalence, hepatitis b, emergency service, hospital, hepatitis		Viruses20260

Clinical Studies 38

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 17
Phase 3 15
N/A 3
Phase 4 2
Phase 1 1

By status:

Completed 33
Recruiting 2
Terminated 2
Active not recruiting 1

By type:

Interventional 35
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 2
multicentricup10 32

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Trial Comparing Whether BEM RZR is Similar to SOF VEL in Patients with Hepatitis C Virus Infection
2025-521096-31-00 — hepatitis c, chronic, hepatitis c, hepatitis, chronic, sofosbuvir, viruses, therapeutics, infections, hepatitis, virus diseases		Phase 3Active not recruiting2025
Phase 2 Study Evaluating the Efficacy and Safety of ALG 000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg Positive and HBeAg Negative Adult Subjects with Chronic Hepatitis B (B SUPREME)
2025-521178-33-00 — tenofovir, safety, hepatitis b virus, herpesviridae infections, hepatitis, chronic, herpesvirus 1, cercopithecine, fumarates, viruses, hepatitis b e antigens, therapeutics, hepatitis b, hepatitis b, chronic, infections, hepatitis, virus diseases		Phase 2Recruiting2025
ANRS HB07 IP Cure B Proof of Concept (PoC) Clinical Trial Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation
NCT05045261 — liver, therapeutics, hepatitis b, environment, hepatitis b, chronic, hepatitis		Phase 2Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS